Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials

By sjmartinez • October 30, 2023

Cheema HA, Shafiee A, Athar MMT, Rafiei MA, Mehmannavaz A, Jafarabady K, Shahid A, Ahmad A, Ijaz SH, Dani SS, Minhas AMK, Nashwan AJ, Fudim M, Fonarow GC. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023 Oct 12;10:1273781. doi: 10.3389/fcvm.2023.1273781. PMID: 37900570; PMCID: PMC10602781.

Tags: Cardiology/Epi, dapagliflozin, empagliflozin, heart failure, HFPEF, Publications, SGLT2I

Interrelationships Between Kansas City Cardiomyopathy Questionnaire Domains, Age, and Sex for Patients With Heart Failure: Findings From the CHAMP-HF and CORC Registries

Girard AA, Jones PG, Fu Z, Sherrod CF 4th, Cantu Martinez O, Greene SJ, Bachmann JM, Fonarow GC, Butler J, Spertus JA, Arnold SV. Interrelationships[...]

Patient-Level Perivascular Adipose Tissue Density Aggregation and Plaque Progression: Plaque-Free vs Plaque-Adjacent Segments

Lee SE, Sung JM, Andreini D, Al-Mallah MH, Budoff MJ, Cademartiri F, Chinnaiyan K, Choi JH, Chun EJ, Conte E, Gottlieb I, Hadamitzky M, Kim[...]

Timeliness of Emergency Care for Intracerebral Hemorrhage Compared With Acute Ischemic Stroke

Royan R, Ikeaba U, Alhanti B, Stamm B, Mac Grory B, Prabhakaran S, Maas MB, Fonarow GC, Messe SR, Mamer LE, Goldstein JN, Saver JL,[...]